By Denny Jacob
TScan Therapeutics shares jumped 23% in premarket trading after a $30 million registered direct offering.
Shares were trading around $3.58. The stock is down about 50% on the year.
The Waltham, Mass.-based clinical-stage biotechnology company said it entered into a securities purchase agreement with Lynx1 Capital Management and investment fund advised by Lynx1 for the sale of about $30 million of pre-funded warrants to purchase up to an aggregate of 7.5 million shares of its voting common stock at a price of $4 per pre-funded warrant.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 26, 2024 09:13 ET (14:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。